examines current advances in the study of the role of miRNAs in
cancer, including
prostate cancer. Issues
Gilyazova, I.R.,
Yankina, M.A.,
Kunsbaeva, G.B.,
Klimentova, E.A.,
Izmaylov, A.A.,
V.N. Pavlov,
Khusnutdinova, E.K. (2016) patient. Bioinformatics analysis was conducted and the most significant mutations in
prostate cancerGilyazova, I.R.,
Ivanova, E.A.,
Bermisheva, M.A.,
Loginova, M.V.,
Asadullina, D.D.,
Ishemgulov, R.R.,
Mustafin, A.T.,
Pavlov, V.N.,
Khusnutdinova, E.K. (2022) of PTEN, rs17878362 of TP53, and rs2699887 of PIK3CA with the risk of
prostate cancer development. As a
GILYAZOVA, I.R.,
KLIMENTOVA, E.A.,
BERMISHEVA, M.A.,
KHUSNUTDINOVA, E.K.,
IZMAILOV, A.A.,
GALIMOVA, E.F.,
SAFIULLIN, R.I.,
GALIMOV, S.N.,
V.N. Pavlov,
BULYGIN, K.V. (2020) in patients with metastatic clear
cell renal
cell carcinoma (ccRCC). Analysis of microRNA expression
KLIMENTOVA, E.A.,
GILYAZOVA, I.R.,
BERMISHEVA, M.A.,
BLINNIKOVA, A. M.,
SAFIULLIN, R.I.,
IZMAILOV, A.A.,
YANG, B.,
PAVLOV ., V.N,
KHUSNUTDINOVA, E.K. (2020) Renal
cell carcinoma (RCC) is a common renal neoplasia of various morphological types, among which